Loading
Epsilogen develops antibody medicines of the IgE class, a type of antibody normally involved in allergy, to rally the immune system against cancer. Its lead medicine, MOv18 IgE, is in an early trial in ovarian cancer that has stopped responding to platinum chemotherapy.
Epsilogen Ltd is based at ARC West London in Hammersmith and describes itself as a pan-isotype antibody company for cancer. Its lead candidate, MOv18 IgE, targets folate receptor alpha and is described by the company as the first IgE therapeutic to enter the clinic. The company-sponsored phase 1b trial EPS101-10-02 (NCT06547840) tests MOv18 IgE in folate receptor alpha-expressing platinum-resistant ovarian cancer, with conditions also listing triple-negative breast cancer and endometrial cancer. In April 2026 the company reported ARPA-H backing for engineered IgA antibody therapeutics. Its first registered cancer trial, NCT06547840, was posted on ClinicalTrials.gov in August 2024.
Shares Folate receptor alpha, Platinum-resistant ovarian cancer.
Shares Platinum-resistant ovarian cancer, Monoclonal antibodies.
Shares Folate receptor alpha, Platinum-resistant ovarian cancer.
Shares Folate receptor alpha, Platinum-resistant ovarian cancer.
Shares Folate receptor alpha, Platinum-resistant ovarian cancer.
Shares Metastatic triple-negative breast cancer, Monoclonal antibodies.
Shares Folate receptor alpha, Platinum-resistant ovarian cancer.
Shares Folate receptor alpha, Platinum-resistant ovarian cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/